Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.

Bernard Zinman Vanita R ArodaJohn B BuseBertrand Cariou Stewart B HarrisSøren Tetens HoffKaren Boje PedersenMads Jeppe Tarp-JohansenEiichi Arakinull null

Published in: Diabetes care (2019)

Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.

Keyphrases

body weight
phase iii
type diabetes
open label
double blind
placebo controlled
clinical trial
glycemic control
phase ii
adipose tissue
metabolic syndrome
skeletal muscle